In a previous post, we looked at innovative methods to assess immunogenicity in biotherapeutics and biosimilars.
The objective though, is to have the least immunogenicity possible (exception made for vaccines). Some factors, especially those which are patient-related, cannot be always controlled but some can definitely be monitored during the production processes of biotherapeutics and biosimilars. Let’s take the case of Host Cell Proteins (HCPs).